Two hyperthermic, rigid, autonomic-unstable syndromes sit at the centre of every psychopharmacology viva: serotonin syndrome vs neuroleptic malignant syndrome. Both are drug-induced emergencies, both can kill, and both present with fever, tachycardia and abnormal muscle tone — which is exactly why examiners love them. The differences are mechanistic, temporal and, on examination, highly patterned.

The discriminator is never the fever. It is when it started, what the patient's mental state is doing, and — decisively — what happens when you lift the limbs: clonus and brisk reflexes on one side, lead-pipe rigidity with absent reflexes on the other. This guide walks through both syndromes feature by feature, with the criteria, the treatments and the mimics you must not miss.

Mechanism: 5-HT excess versus D2 blockade

Serotonin syndrome is a toxidrome caused by overstimulation of serotonergic receptors — principally central and peripheral 5-HT2A receptors. It follows initiation, dose escalation or overdose of a serotonergic drug, or (classically) an interaction: a monoamine oxidase inhibitor plus an SSRI, tramadol, pethidine, dextromethorphan or St John's wort; an SSRI plus linezolid or methylene blue; triptans on an SSRI background. The commonest real-world cause in most series is simply an overdose of one serotonergic drug, not an interaction — a point emphasised in Boyer and Shannon's NEJM review.

Neuroleptic malignant syndrome (NMS) is a dopaminergic-blockade syndrome: antagonism at striatal, hypothalamic and autonomic D2 receptors by an antipsychotic — most often after a high-potency agent, an abrupt dose increase or parenteral administration. A second, equally examinable route is withdrawal of dopaminergic medication: stopping levodopa or a dopamine agonist in Parkinson's disease produces the same picture, often labelled parkinsonism–hyperpyrexia syndrome.

Serotonin syndrome vs neuroleptic malignant syndrome: feature by feature

Feature Serotonin syndrome Neuroleptic malignant syndrome
Mechanism 5-HT2A receptor overstimulation D2 receptor blockade (or dopaminergic withdrawal)
Typical trigger SSRI/SNRI/MAOI/tramadol/linezolid — interaction or overdose Antipsychotic start, dose increase or parenteral route; stopping levodopa
Onset Hours — commonly within 6–24 h of the drug or dose change Days to weeks — usually 1–30 days after exposure
Mental state Agitation, confusion, delirium — hyperactive Obtundation, stupor, marked psychomotor slowing — hypoactive
Muscle tone Mild to moderate rigidity; lower limbs often worse than upper Severe generalised "lead-pipe" rigidity
Reflexes Hyperreflexia with inducible or ocular clonus Bradyreflexia or hyporeflexia
Temperature Hyperthermia, often marked (hyperthermia >38 °C supports the diagnosis) Hypothermia or hyperthermia; hyperthermia indicates severity
Autonomic features Diaphoresis, mydriasis, hypertension, tachycardia — adrenergic surge Labile blood pressure, tachycardia, sweating — unstable rather than surging
GI function Hyperactive: diarrhoea, increased bowel sounds Hypoactive: ileus, retained urine
Laboratory clues CK usually normal or mildly raised Markedly raised CK with rhabdomyolysis, leukocytosis, metabolic acidosis
Course after stopping Resolves over 24–72 h Persists days to weeks; rigidity and CK lag behind
Targeted treatment Cyproheptadine (5-HT2A antagonist) plus benzodiazepines Dantrolene plus bromocriptine (dopamine agonist)

Exam trap

Hyperreflexia and clonus favour serotonergic toxicity; lead-pipe rigidity with bradyreflexia favours NMS. When the vignette describes a patient with fever, rigidity and "knee-jerk reflexes are difficult to elicit", the tempting move is to name whichever syndrome matches the drug on the chart. Reflexes decide: inducible clonus, ocular clonus and exaggerated tendon reflexes point to serotonergic toxicity, whereas profound rigidity with diminished reflexes and a quiet, obtunded patient points to NMS. Deep tendon reflexes are also the fastest thing you can test at the bedside in an OSCE — say out loud what you are doing.

Recognising the syndromes with criteria

The Hunter Serotonin Toxicity Criteria (Dunkley and colleagues, 2003) are the best-validated instrument and the ones to quote. In the context of a serotonergic agent, one of the following suffices: spontaneous clonus; inducible clonus plus agitation or sweating; ocular clonus; tremor plus hyperreflexia; or hypertonia with temperature above 38 °C plus ocular or inducible clonus. In their derivation the criteria outperformed the older Sternbach criteria — commonly cited performance is around 84% sensitivity and 97% specificity against expert diagnosis. Note that normal reflexes effectively exclude mild to moderate serotonin toxicity.

NMS has no equivalent bedside rule; recognition is clinical plus contextual — exposure timeline, rigidity, CK and the exclusion of mimics. Diagnostic frameworks such as Davis and colleagues' description emphasise exposure to a dopamine antagonist, fever, muscle rigidity, autonomic instability and raised CK, with an otherwise negative work-up for infection and metabolic causes.

Management: what you actually do

Serotonergic toxicity. Stop every serotonergic agent immediately. Then supportive care: benzodiazepines for agitation and tremor (they reduce muscle activity and are the first-line symptomatic drug), aggressive cooling for hyperthermia, and fluid resuscisation. Cyproheptadine, a 5-HT2A antagonist, is the specific antidote for moderate-to-severe cases — the widely quoted regimen is an initial 12 mg oral dose followed by 2 mg every two hours, titrating to control of signs, to a maximum of 32 mg per day (use with care if the patient is obtunded, given aspiration risk). Evidence is case-series level, but it is standard teaching. Severe cases with hyperthermia above 38.5 °C need intensive care, intubation and neuromuscular paralysis; mortality in collected series is around 10% and is driven almost entirely by the hyperthermia.

NMS. Stop the antipsychotic and any other dopamine antagonist; supportive care in a monitored bed is the foundation. Add dantrolene (a peripheral muscle relaxant — commonly described as 0.25–1 mg/kg IV every six hours, to a maximum of about 10 mg/kg/day) for rigidity and hyperthermia, and bromocriptine (a dopamine agonist, conventionally started at 2.5 mg every eight hours and titrated upwards) to reverse the dopaminergic block; amantadine is an alternative when bromocriptine is not tolerated. Refractory cases have been treated with ECT. Resolution is slow: rigidity and CK take days to weeks, and recurrence risk rises with re-exposure to antipsychotics.

Do not forget the mimics. Anticholinergic toxicity gives fever, delirium and mydriasis but dry skin, absent sweating and reduced bowel sounds. Malignant catatonia presents with rigidity and autonomic instability without a drug trigger and characteristically improves with ECT. Thyrotoxicosis, CNS infection, sepsis and meningitis must be excluded with the appropriate work-up, and malignant hyperthermia follows an anaesthetic trigger rather than a psychiatric drug history. The history — what was started, stopped, increased or swallowed, and when — separates them faster than any single sign.

If you want the wider psychopharmacology picture organised for revision — receptor profiles, interactions and adverse-effect patterns together — Preppsy's structured concept library links each toxidrome to the drugs that cause it, and Preppsy's AI tutor will put you through rapid-fire differential questions in the style of a CASC or oral exam.

Frequently asked questions

How can you tell serotonin syndrome from neuroleptic malignant syndrome at the bedside?

Three things decide it: onset (hours for serotonin syndrome, days to weeks for NMS), mental state (agitated and confused versus obtunded and slowed), and reflexes (hyperreflexia with inducible or ocular clonus versus lead-pipe rigidity with bradyreflexia). Supportive clues are hyperactive bowel sounds and diarrhoea in serotonin syndrome against ileus in NMS, and a markedly raised CK in NMS. Always take the drug timeline — a new SSRI, an MAOI interaction or an overdose points to serotonin toxicity; an antipsychotic increase or stopped levodopa points to NMS.

How quickly does serotonin syndrome develop after an overdose?

Fast — usually within hours, and classically within 6 to 24 hours of ingestion or of a serotonergic interaction. That speed is itself diagnostic information: a patient who deteriorates on the same day a serotonergic drug is started or increased is far more likely to have serotonin toxicity than NMS, which typically evolves over one to several days and can take up to a month after exposure.

What is the first-line treatment for serotonin syndrome?

Immediate withdrawal of all serotonergic drugs plus supportive care — benzodiazepines for agitation and tremor, cooling and fluids. Cyproheptadine is added for moderate-to-severe cases, conventionally 12 mg initially and then 2 mg every two hours to a maximum of 32 mg per day. Severe hyperthermia requires intensive care with intubation and neuromuscular paralysis; antipyretics are of little value because the fever is generated by muscle activity.

How long does neuroleptic malignant syndrome take to resolve?

Days to weeks. Rigidity, temperature and creatine kinase usually improve over about a week with the antipsychotic stopped and dantrolene or bromocriptine started, but full resolution of muscle rigidity and CK elevation can take considerably longer, and psychomotor symptoms may lag. Serotonin syndrome, by contrast, typically settles within 24 to 72 hours of removing the causing drug.

Key takeaways

  • Serotonergic toxicity = 5-HT2A overstimulation, hours after exposure; NMS = D2 blockade, days to weeks after exposure.
  • Examine the reflexes: hyperreflexia + clonus = serotonergic toxicity; lead-pipe rigidity + bradyreflexia = NMS.
  • Mental state separates them too — agitated/delirious versus obtunded/slowed.
  • Use the Hunter Serotonin Toxicity Criteria for serotonin toxicity; CK, timeline and exclusion for NMS.
  • Treatment: stop the drug, support, then cyproheptadine (5-HT2A) versus dantrolene plus bromocriptine.
  • Exclude the mimics: anticholinergic toxidrome, malignant catatonia, infection, thyrotoxicosis, malignant hyperthermia.

Drill both toxidromes until the discriminators are automatic with Preppsy's spaced-repetition flashcards, then test yourself under pressure with a full mock exam covering psychopharmacology across MRCPsych and USMLE.

Cover image: “Serotonin Syndrome vs NMS (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.